Navigation Links
Ambion Offers Gene Expression Profiling Service

's Array Services offers much more than what a typical core laboratory can. It is a complete service microarray information group, which aims to maximize the quantity and quality of information that can be obtained from a microarray experiment. The Array Services' staff of experienced biologists, statisticians, and bioinformatics specialists will work with you to organize the most effective and economical approach to accomplish your experimental goals by:

Helping to formulate a concise experimental question

Setting up an experimental design that includes biological and analytical perspectives

Replication for efficient analysis
Sampling
Selection of controls
Cost efficacy: fewest arrays for the most information

Recommending statistical analyses to meet your goals


Target aRNA Preparation

Ambion can prepare aRNA samples starting from both eukaryotic and prokaryotic RNA by using the best linear RNA amplification product on the market: MessageAmp II aRNA Amplification Kit.

Ambion Services uses the MessageAmp II Kit, which allows reproducible amplification from small total RNA samples:

>500 ngone round of amplification

<500 ngtwo rounds of amplification

All amplified samples are then inspected on an Agilent 2100 bioanalyzer to confirm quality (i.e. size and yield).


Hybridization/Scanning

All reagents (hybridization and washes) pass strict quality control standards


Data Analysis'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Ambion Custom
2. Ambion Custom: Made-to-Order
3. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
4. Your Data: Detection of Oocyte-specific Gene Expression Using Ambions Cells-to-cDNA Kit
5. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
6. An Epitope Tagging Vector for Gene Expression in Mammalian Cells
7. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
8. High-Level Expression of Peanut Allergens Affected by Rare Codon Usage
9. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
10. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
11. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Ambion Offers Gene Expression Profiling Service

Breaking Biology News(10 mins):Tropical birds waited for land crossing between North and South America: UBC study 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 477 percent of European pigs are castrated without anesthetic 2Nurses from HCA Hospitals Nationwide Rally in Support of MountainView RNs Today 55173 1Nurses from HCA Hospitals Nationwide Rally in Support of MountainView RNs Today 55173 2Smokers Twice As Likely to Get TB 55170 1Smokers Twice As Likely to Get TB 55170 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 1FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 3FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 4FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 5FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 6FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 7FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 8FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 9FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 10